Focusing on nice setups next week (and news out on a past winner)

Published: Thu, 01/26/17


SMS alerts can make the difference between a profitable trade and a missed opportunity.
 Text “alert” to 97000 to receive our instant, reliable and free SMS alerts.
 

Hello fellow investors / traders,
 
Sorry about the past couple of alerts. Today's play wasn't particularly great. Although it closed even on the day, and getting in and out shouldn't have been a problem, there was just too much overhead resistance for it to break out like it had in the past.

Nevertheless, we have been super profitable with our recent alerts over the past couple of months. And I'm closely studying a few opportunities for next week.

Speaking of past picks, last week we alerted you to OBMP, a clinical stage pharma company,  and it gained 28% in one day on strong volume. It has since pulled back, but today it bounced big after the Company announced some big news during the day.

Check out the news below and keep OBMP on your radar in the coming days and weeks, looking for opportunities on pullbacks as I think this has more longer term upside to come.

Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials

BATON ROUGE, LA--(Marketwired - January 26, 2017) - OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today provides the latest clinical data of ProscaVax, the Company's novel therapeutic prostate cancer vaccine.

In the ongoing Phase 1 clinical trial, ProscaVax is being evaluated for safety and efficacy in prostate specific antigen (PSA) recurrent prostate cancer in hormone-naïve and hormone-independent patients. Per protocol, 20 patients are expected to be enrolled in the 1a portion of the study, with therapy consisting of six ProscaVax induction vaccinations at a single dose. To date, 16 prostate cancer patients have enrolled in the trial.

The trial is being hosted at the University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, California under an IND from the U.S. Food and Drug Administration with funding from the U.S. Navy Cancer Vaccine Program.

Additional preliminary data from the trial shows ProscaVax to provide a meaningful clinical benefit to prostate cancer patients. These data include:

  • 15 of 20 patients* in the Phase 1a portion of the trial have received at least one vaccine injection and 14 patients have received all 6 vaccines.
  • None of the 15 patients who have had at least one vaccine have had a DLAE.
  • None of the 14 patients who have received all 6 vaccines in the Phase 1a have had a DLAE.
  • 9 of the 14 patients that have received 6 vaccines have had increased PSA doubling time, suggesting ProscaVax is slowing tumor growth.
  • 11 of the 13 patients** that have received 6 vaccines have had increased immune responses to PSA as determined with a Lymphocyte Blastogenesis Assay by 31 weeks post-vaccine.
  • 3 of the 14 patients that have received all 6 vaccines have experienced disease progression (one radiological, two PSA)

Data from this trial combined with previous in-house studies have established a strong safety profile for ProscaVax, while providing evidence of a therapeutic benefit that warrants larger clinical trials. OncBioMune is preparing to enter a Phase 2/3 trial in Mexico through a Joint Venture with its acquisition target and Mexican partner Vitel Laboratorios S.A. de C.V. Inclusion criteria for the Phase 2/3 trial will be similar to the ongoing Phase 1 trial. A second Phase 2 trial is planned in the United States at a prominent Northeast university cancer center evaluating ProscaVax at disease presentation in early-stage prostate cancer patients in the "active surveillance" population.

"We're very excited by the updated data that once again supports our thesis that ProscaVax can provide a meaningful benefit to prostate cancer patients without the horrible side effects well known to accompany today's approved therapies," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "We greatly look forward to our upcoming Phase 2 studies where we will be adding six ProscaVax booster injections, which we believe has the potential to further increase efficacy for both early and late-stage prostate cancer patients."

* one enrolled patient failed a screening test and was forced to withdraw from study

** one patient was not evaluated with LBA due to a blood sample error by the hospital

http://finance.yahoo.com/news/latest-clinical-data-oncbiomune-supports-204759215.html


I'll touch base over the weekend with new trade ideas for next week.
 
 
 
To your success,
SmallCapMomo.com

 
---------------------------------------------------------------------- 
 
Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity.
 

Disclaimer
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
SmallCapMomo.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. The disclaimer is to be read and fully understood before using our site, or joining our email list. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein.  Instead SmallCapMomo.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. SmallCapMomo.com does not offer such advice or analysis, and SmallCapMomo.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, SmallCapMomo.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SmallCapMomo.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SmallCapMomo.com is not responsible for any claims made by the companies advertised herein. SmallCapMomo.com may receive compensation and its employees and affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in SmallCapMomo.com statements and opinions and such statements and opinions cannot be considered independent. SmallCapMomo.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, SmallCapMomo.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. SmallCapMomo.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the companies profile. SmallCapMomo.com has previously been compensated three thousand dollars via electronic transfer from a non-affiliated third party for the profile of OBMP. SmallCapMomo.com may on occasion accept compensation in restricted or free-trading shares for it's marketing services of the company being profiled, and the third party that might have compensated SmallCapMomo.com may hold free-trading shares of the company being profiled and could very well be selling shares of the companies stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.  If SmallCapMomo.com ever accepts compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services.